MedTrace Logo

Treatment Pathway of Patients Suffering From a Breast Cancer Related Lymphoedema

NCT02506530 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 93

Last updated 2025-12-05

No results posted yet for this study

Summary

This study will assess the benefit of LPG Cellu M6 in addition of intensive decongestive treatment in reducing secondary lymphoedema in breast cancer.

Conditions

  • Lymphedema

Interventions

DEVICE

Cellu M6

Use of Cellu M6

PROCEDURE

intensive decongestive treatment

intensive decongestive treatment

Sponsors & Collaborators

  • LPG SYSTEMS

    collaborator UNKNOWN

  • University Hospital, Toulouse

    lead OTHER

Principal Investigators

  • Julie MALLOIZEL-DELAUNAY, MD · University Hospital, Toulouse

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02506530 on ClinicalTrials.gov